| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology, Glostrup Hospital, University of Copenhagen, Glostrup Copenhagen, Denmark.
Address correspondence and reprint requests to Dr. Finn Sellebjerg, Department of Neurology, Glostrup Hospital, University of Copenhagen, 57 Nordre Ringvej, DK-2600 Glostrup Copenhagen, Denmark.
Objective: There is only limited evidence from adequately controlled clinical trials to support high-dose methylprednisolone therapy for attacks of multiple sclerosis (MS) and none supporting oral administration. We assessed the effect of oral high-dose methylprednisolone therapy in attacks of MS.
Methods: Twenty-five patients with an attack of MS lasting less than 4 weeks were randomized to placebo treatment. Twenty-six patients received oral methylprednisolone (500 mg once a day for 5 days with a 10-day tapering period). The patients received scores on the Scripps Neurological Rating Scale (NRS) and Kurtzke Expanded Disability Status Scale. The symptoms were scored on a visual analog scale (VAS) before treatment and after 1, 3, and 8 weeks of treatment. Primary efficacy measures were NRS and VAS scores in the first 3 weeks and changes in NRS score and answers to an efficacy questionnaire administered after 8 weeks of treatment.
Results: Changes in NRS scores among methylprednisolone- and placebo-treated patients differed significantly in the first 3 weeks and after 8 weeks(p = 0.005 and p = 0.0007). VAS scores the first 3 weeks and treatment efficacy after 8 weeks also favored a beneficial effect of methylprednisolone treatment (p = 0.02 and p = 0.05). After 1, 3, and 8 weeks, 4%, 24%, and 32% in the placebo group and 31%, 54%, and 65% in the methylprednisolone group had improved one point on the Expanded Disability Status Scale score (all p < 0.05). No serious adverse events were seen.
Conclusion: Oral high-dose methylprednisolone is recommended for managing attacks of MS.
Supported by grants from the Danish Multiple Sclerosis Society, the Johnsen Memorial Foundation, and Pharmacia & Upjohn.
Received September 9, 1997. Accepted in final form April 24, 1998.
This article has been cited by other articles:
|
|
 |
|
  S Kopke, J Kasper, I Muhlhauser, M Nubling, and C Heesen Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial Multiple Sclerosis, January 1, 2009; 15(1): 96 - 104. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Glass-Marmor, T. Paperna, Y. Ben-Yosef, and A. Miller Chronotherapy using corticosteroids for multiple sclerosis relapses J. Neurol. Neurosurg. Psychiatry, August 1, 2007; 78(8): 886 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E T Lim, F Sellebjerg, C V Jensen, D R Altmann, D Grant, G Keir, E J Thompson, and G Giovannoni Acute axonal damage predicts clinical outcome in patients with multiple sclerosis Multiple Sclerosis, October 1, 2005; 11(5): 532 - 536. [Abstract] [PDF]
|
|
|
|
|
|
J S Sloka and M Stefanelli The mechanism of action of methylprednisolone in the treatment of multiple sclerosis Multiple Sclerosis, August 1, 2005; 11(4): 425 - 432. [Abstract] [PDF]
|
|
|
|
 |
|
 S. A. Rizvi and K. Bashir Other therapy options and future strategies for treating patients with multiple sclerosis Neurology, December 28, 2004; 63(12_suppl_6): S47 - S54. [Abstract] [Full Text]
|
|
|
|
|
|
J. Rio, C. Nos, I. Bonaventura, R. Arroyo, D. Genis, B. Sureda, J. R. Ara, L. Brieva, J. Martin, A. Saiz, et al. Corticosteroids, ibuprofen, and acetaminophen for IFN{beta}-1a flu symptoms in MS: A randomized trial Neurology, August 10, 2004; 63(3): 525 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Sellebjerg, C V Jensen, H B. Larsson, and J L Frederiksen Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis Multiple Sclerosis, February 1, 2003; 9(1): 102 - 107. [Abstract] [PDF]
|
|
|
|
|
|
J. Reess, J. Haas, K. Gabriel, A. Fuhlrott, and M. Fiola Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-la (AVONEX(R)) therapy Multiple Sclerosis, September 1, 2002; 8(1_suppl): 15 - 18. [Abstract] [PDF]
|
|
|
|
|
|
P. A. Calabresi Considerations in the treatment of relapsing-remitting multiple sclerosis Neurology, April 23, 2002; 58(90084): S10 - 22. [Abstract] [Full Text]
|
|
|
|
|
|
J Reess, J Haas, K Gabriel, A Fuhlrott, and M Fiola Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX(R)) therapy Multiple Sclerosis, February 1, 2002; 8(1): 15 - 18. [Abstract] [PDF]
|
|
|
|
|
|
R. Zivadinov, R. A. Rudick, R. De Masi, D. Nasuelli, M. Ukmar, R. S. Pozzi-Mucelli, A. Grop, G. Cazzato, and M. Zorzon Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS Neurology, October 9, 2001; 57(7): 1239 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M Miller, B. Weinstock-Guttman, F. Bethoux, J.-C. Lee, G. Beck, V. Block, L. Durelli, L. LaMantia, D. Barnes, F. Sellebjerg, et al. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations Multiple Sclerosis, August 1, 2000; 6(4): 267 - 273. [Abstract] [PDF]
|
|
|
|
|
|
L. M. Metz, D. Sabuda, R. J. Hilsden, R. Enns, and J. B. Meddings Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis Neurology, December 1, 1999; 53(9): 2093 - 2093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Sellebjerg, H. S. Nielsen, J. L. Frederiksen, and J. Olesen A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis Neurology, April 1, 1999; 52(7): 1479 - 1479. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
